CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy by Kinstrie, Ross et al.
Leukemia
https://doi.org/10.1038/s41375-019-0684-5
ARTICLE
Chronic myelogenous leukemia
CD93 is expressed on chronic myeloid leukemia stem cells and
identifies a quiescent population which persists after tyrosine kinase
inhibitor therapy
Ross Kinstrie1 ● Gillian A. Horne 1 ● Heather Morrison1 ● David Irvine1 ● Chinmay Munje1 ●
Eduardo Gómez Castañeda 1 ● Hothri A. Moka1 ● Karen Dunn 1 ● Jennifer E. Cassels1 ● Narissa Parry1 ●
Cassie J. Clarke1 ● Mary T. Scott1 ● Richard E. Clark2 ● Tessa L. Holyoake1 ● Helen Wheadon1 ● Mhairi Copland 1
Received: 8 July 2019 / Revised: 17 November 2019 / Accepted: 5 December 2019
© The Author(s) 2020. This article is published with open access
Abstract
The introduction of BCR-ABL tyrosine kinase inhibitors has revolutionized the treatment of chronic myeloid leukemia
(CML). A major clinical aim remains the identification and elimination of low-level disease persistence, termed “minimal
residual disease”. The phenomenon of disease persistence suggests that despite targeted therapeutic approaches, BCR-ABL-
independent mechanisms exist which sustain the survival of leukemic stem cells (LSCs). Although other markers of a
primitive CML LSC population have been identified in the preclinical setting, only CD26 appears to offer clinical utility.
Here we demonstrate consistent and selective expression of CD93 on a lin−CD34+CD38−CD90+ CML LSC population and
show in vitro and in vivo data to suggest increased stem cell characteristics, as well as robust engraftment in patient-derived
xenograft models in comparison with a CD93− CML stem/progenitor cell population, which fails to engraft. Through bulk
and single-cell analyses of selected stem cell and cell survival-specific genes, we confirmed the quiescent character and
demonstrate their persistence in a population of CML patient samples who demonstrate molecular relapse on TKI
withdrawal. Taken together, our results identify that CD93 is consistently and selectively expressed on a lin−CD34+
CD38−CD90+ CML LSC population with stem cell characteristics and may be an important indicator in determining poor
TKI responders.
Introduction
Chronic myeloid leukemia (CML) originates from a con-
stitutively active tyrosine kinase, BCR-ABL. In CML, not
all leukemia stem cells (LSCs) are eradicated by tyrosine
kinase inhibitors (TKIs) in vitro and a population of
lin−CD34+ CML progenitors have the ability to remain
quiescent and engraft NSG mice [1–4]. Furthermore, cells of
a similar phenotype have been identified in the bone marrow
(BM) of imatinib-treated CML patients in complete cyto-
genetic response [5]. These findings verify CML LSCs are
not absolutely dependent on BCR-ABL activity for their
survival, and may determine disease persistence, high-
lighting those patients who are at high risk of molecular
recurrence on TKI withdrawal [6, 7]. Although many labs
have performed extensive analyses to identify potential
surface markers of primitive cell populations in the pre-
clinical setting, including CD26 [8–10], and IL1-RAP
[11, 12], these markers show variability and have, there-
fore, not yet been translated into routine clinical practice.
However, CD26 is promising, with recent data suggesting a
correlation between CD26 expression and treatment
response, as well as a Lin−CD34+CD38−/lowCD45RA−
cKIT−CD26+ population being identified as a potential
therapeutic target at a single-cell level [13]; the diagnostic
potential of CD26 is currently being evaluated within clin-
ical trials [14, 15].
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We present for the first time, evidence for the role of
CD93 as a primitive marker with functional relevance in
chronic phase (CP)-CML LSCs. A variety of functions for
CD93 have been described, including leukocyte migration,
and cell adhesion, and it has been identified on a number of
cell types, including cells of a myeloid origin, stem cells,
endothelial cells, and platelets [16, 17]. Despite this, its
purpose and mechanisms in myeloid malignancy have yet to
be fully elucidated. It has, however, been shown to offer
potential as a biomarker for an AML LSC population in
MLL-rearranged AML [18]. Here, we demonstrate con-
sistent and selective expression of CD93 on a lin−
CD34+CD38−CD90+ CP-CML LSC population and show
robust engraftment of this population in patient-derived
xenograft (PDX) models in comparison with CD93− CML
stem/progenitor cells, which fail to engraft, confirming its
relevance in CP-CML.
Methods
Human samples
Informed consent was obtained in accordance with the
Declaration of Helsinki and with approval from Greater
Glasgow and Clyde NHS Trust Ethics Committee. BM
samples from trial entry of the DESTINY clinical trial
(NCT01804985) [19] were utilized to assess cell popula-
tions in patients with/without molecular recurrence on
TKI discontinuation. Sample details are listed in Table S1.
CD34+ cells were purified and cryopreserved as previously
described [20]. A minimum of three biological replicates
were performed for each experiment in the first instance
with more biological replicates included if patient hetero-
geneity was observed.
Prior to FACS sorting, CD34+ cells were thawed over
20 min in DAMP solution and incubated overnight in serum
free medium with high growth factors (SFM+HGF) to
maximize recovery post thaw, as previously described [2].
Following overnight incubation, CD34+ cells were cultured
in a ‘physiological’ growth factor cocktail (1 in 100 dilu-
tion, SFM+HGF).
Drugs and reagents
Imatinib, dasatinib, and nilotinib (all LC laboratories) were
made into stock solutions of 10 mM in DMSO. Dilutions to
working concentrations were made with media.
Flow cytometry and cell sorting
Cells were stained using the following antibody cocktail (all
BD Biosciences apart from CD93-PE from eBioscience);
lineage cocktail-FITC [CD3 (MφP9), CD14 (3G8), CD16
(NCAM16.2), CD19 (SJ25C1), CD20 (SK7), CD56 (L27)],
CD34-PerCP (8G12), CD38-V450 (HIT2), CD45RA-APC
H7 (HI100), CD90-PE Cy7 (5E10), CD123-APC (7G3),
and CD93-PE (R3). Immunophenotypic analysis and cell
sorting of normal and CML samples was performed fol-
lowing antibody staining on a FACSCanto or FACSAria
(BD Biosciences). FACS data were analyzed with FACS
Diva software (Becton Dickinson) or FlowJo (TreeStar).
In vitro colony-forming cell (CFC), replating and
long-term culture-initiating cell (LTC-IC) assays
2000 FACS-sorted cells from stem and progenitor sub-
populations were plated in duplicate in Methocult optimum
(H4034, Stem Cell Technologies). Following incubation at
37° for 10–12 days, colonies were counted. For replating,
50 individual primary colonies per sample were picked and
re-suspended in 200 μl Methocult in 96 well plates, incu-
bated at 37° for 10–12 days before positive wells counted.
Primary CP-CML samples were sorted for Lin−CD34+
CD93−/+ cells and cultured overnight. Cells were washed
and inoculated into pre-prepared long-term cultures com-
prising a stromal feeder layer (1:1 mix of irradiated (80 Gy)
SL/SL and M210B4 murine fibroblasts) in long-term mye-
loid culture medium (MyeloCult supplemented with
hydrocortisone; Stem Cell Technologies) [21]. Cultures
were maintained for 5 weeks with 50% media changes
performed weekly. Each well was harvested, counted, and
seeded into Methocult to perform CFC assays.
Murine xenotransplantation assay
Experiments were performed in accordance with the local
ethical review panel, the UK Home Office Animals Scien-
tific Procedures Act, 1986, and UK Coordinating Com-
mittee on Cancer Research and National Cancer Research
Institute guidelines. Animals were kept in regulated facil-
ities, monitored daily, and all experiments complied with
UK Home Office guidelines. Mice were genotyped by
Transnetyx. NOD.Cg-PrkdcscidIL2rgtm1Wjl/SzJ (NSG) mice
were purchased from Charles River Laboratories, UK.
Sample size was dictated by cell number from primary
samples. No randomization or blinding was used during
murine xenotransplantation assays.
The NSG mouse model was used to assay human LSCs
with in vivo engraftment capacity (SCID-repopulating cells
or SRC). CP-CML lin−CD34+CD93+ or lin−CD34+CD93−
cells were isolated by FACS (1 × 106 cells/mouse), washed
and transplanted via tail vein injection into sub-lethally
irradiated (200 cGy) 8–12-week-old NSG mice. Mice were
euthanized after 16 weeks and BM obtained. To assess
human cell engraftment, cells were labeled with anti-human
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CD45 (H130), CD33 (P67.6), and CD19 (SJ25C1) anti-
bodies (all BD Biosciences) prior to analysis by flow
cytometry. Human CD45+CD33+ cells were isolated by
FACS and analyzed by FISH for the BCR-ABL gene rear-
rangement. For in vivo TKI treatments, NSG mice were
transplanted with 1 × 106 FACS-sorted CD34+ cells as
above, and left for 12 weeks to allow engraftment. Mice
were then treated with 50 mg/kg nilotinib by oral gavage
once daily for 28 days before euthanizing and BM extrac-
ted. Human cells were analyzed by flow cytometry fol-
lowing labeling with anti-human antibodies against CD45
(H130), CD33 (P67.6), CD34 (8G12), CD38 (HIT2) all BD
Biosciences, and CD93 (R3) (eBiosciences).
Microarray and bioinformatic analysis
Cell populations were FACS-sorted into: Hematopoietic
stem cell (HSC)/LSC (Lin−CD34+CD38−CD45RA−CD90+),
multipotent progenitor (MPP; Lin−CD34+CD38−CD45RA−
CD90−), common myeloid progenitor (CMP; Lin−CD34+
CD38+CD45RA−CD123+), granulocyte-macrophage pro-
genitor (GMP; Lin−CD34+CD38+CD45RA+CD123+), and
megakaryocyte-erythroid progenitor (MEP; Lin−CD34+
CD38+CD45RA−CD123−). RNA extracted from stem/pro-
genitor cell subpopulations was analyzed with Affymetrix
Human Gene 1.0 ST arrays (GEO accession number
GSE47927 [22]) by Polyomics, University of Glasgow. Using
R/Bioconductor, data were RMA normalized and subse-
quently analyzed using a modified LIMMA protocol [23].
Differential expression was identified by LIMMA using
q < 0.05.
Cytogenetics and fluorescence in situ hybridization
(FISH) analysis
FISH was performed with the LS1 BCR-ABL Dual Color
FISH probe (Abbott Diagnostics) according to the manu-
facturer’s instructions. Results are presented as percent
of positive interphases as calculated in a minimum of
100 cells.
RT-PCR
RNA was extracted using the Qiagen RNEasy Minikit as
per the manufacturer’s instructions and reverse transcribed
using the high-capacity cDNA synthesis kit (Applied Bio-
systems). Primers were designed using NCBI software
(Table S2). Quantitative RT-PCR was performed on a
Taqman 7900 instrument (Applied Biosystems) and using
Fluidigm technology. Gene expression was determined
relative to four housekeeping genes and expressed as 2−ΔCt
or compared with an untreated calibrator (2−ΔΔCt) [24].
Multiplex PCR was performed as per [25].
Single-cell analysis of transcription
RNA was extracted from lin−CD34+, lin−CD34+CD38−
CD90+CD93−, and lin−CD34+CD38−CD90+CD93+
populations, reverse transcribed, and 14 cycles of gene-
specific amplification performed using the Applied Bio-
system pre-amplification kit with relevant primer sets.
Following amplification, 2 uL of the resultant product was
used for multiplex PCR reaction, as described [25]. The
rest of the resultant products were loaded in triplicate onto
pre-primed 96 × 96 Fluidigm microfluidic dynamic arrays
and analyzed according to the manufacturer’s instructions.
To assess single-cell gene expression, Fluidigm C1™ was
used. Analysis was performed using R 3.3.3 under macOS
10.13.2. Data processing and normalization were per-
formed independently for each chip. Only those genes
with detectable expression in at least 10 CD93+ and 10
CD93− cells within the same chip were analyzed. All the
expression values were normalized using the –ΔΔCt
method [24].
Statistical analysis
Statistics were calculated using R-3.4.3 and Prism 6 soft-
ware (GraphPad Software, Inc). Data are presented as the
mean ± SD. Statistical significance was determined via
Student’s t test (p < 0.05 was considered significant).
Single-cell statistical analysis was performed using
Kolmogorov–Smirnov test and corrected for multiple
comparisons using Benjamini–Hochberg method [23, 26].
The correlation between the –ΔCts and the frequency of
detectable expression was performed using Pearson’s r
correlation coefficient.
Results
CML stem cells are more proliferative than normal
HSCs
To determine transcriptomic and functional differences
between CML LSCs and normal HSCs, normal (n= 3) and
CP-CML (n= 6) samples were FACS-sorted into HSC/
LSC, CMP, GMP, and MEP subpopulations (Fig. 1a).
Within the HSC/LSC compartment, CML LSCs demon-
strated significantly increased proliferation (14-fold expan-
sion, p < 0.001) compared with normal HSCs (no
expansion) after 5 days in vitro culture in physiological
growth factors (Fig. 1b). There was variable expansion in
both normal and CML CMP and GMP subpopulations, with
no significant difference between CML and normal.
Expansion of CML MEP was significantly reduced com-
pared with normal. Equivalent numbers of CML LSCs
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produced approximately fourfold more colonies in CFC
assays than normal HSCs (329 ± 46 versus 86 ± 17 per 2000
cells, respectively; p < 0.05) (Fig. 1c). There was no sig-
nificant difference between normal and CML CMP, GMP,
and MEP subpopulations in the number of colonies pro-
duced. FISH demonstrated that >90% of CML LSCs from
all patient samples were BCR-ABL positive.
CML LSCs have a less primitive gene expression
profile than normal HSCs
Next, we characterized the gene expression profiles of the
different CML and normal subpopulations (GEO accession
number GSE47927). Data were RMA normalized and ana-
lyzed using a modified LIMMA/Bioconductor protocol. The
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Fig. 1 CML LSCs are more proliferative than normal HSCs. a A
representative sorting strategy of CP-CML samples is depicted. b Fold
expansion after 5 days (mean ± standard deviation) are shown (**p <
0.01; ***p < 0.001). c Colony counts are represented (mean ± standard
deviation) per 2000 starting cells to allow comparison between groups
(*p < 0.05). d Principal component analysis (PCA) of the gene
expression profiles from GSE47927 was used to identify global dif-
ferences between normal and CP-CML. An individual point within the
axes represents each microarray and each subpopulation grouping by a
different color. Separate PCAs of normal and CP-CML subpopula-
tions. e PCA of normal and CP samples overlapped. f A volcano plot
from the same dataset showing the deregulation of genes in a com-
parison of Lin−CD34+CD38−CD90+ cells from six CP-CML samples
compared with three normal samples (GSE47927). Areas of sig-
nificance are indicated by a dark green (equivalent to q ≤ 0.01) or light
green (equivalent to q ≤ 0.05) background. Genes reaching significance
are colored red (q ≤ 0.01) or orange (q ≤ 0.05); non-significant genes
are gray.
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gene expression profile of CML LSCs was determined to be
more akin to normal primitive progenitor cells, and not normal
HSCs, as represented through Principal Component Analyses
(PCA) where, when plotted together, LSCs from patients with
CP-CML (n= 6) have a global gene expression signature that
appears more mature than normal HSCs (n= 3) and is posi-
tioned overlapping both normal and CML progenitor sub-
populations (Fig. 1d, e). Although not surprising that CP-CML
LSCs display a myeloid-based transcriptome compared with
normal HSCs, it confirms the ability of mature progenitor
populations to behave as ‘stem cells’ in the CML model.
Within this dataset (GSE47927), 1217 genes were deregulated
between CP-CML LSCs and normal HSCs (Fig. 1f).
We utilized this gene expression dataset to evaluate the
expression of cell surface markers. Using z scores to nor-
malize the gene expression for each sample, we plotted
heatmaps using R/Bioconductor. This demonstrated the
variable expression of cell surface markers between CP-
CML LSCs and normal HSCs (Fig. S1). Cell surface mar-
kers expressed were significantly altered between the CML
LSC and normal HSC populations (statistically significant
cell surface markers shown in Fig. 2a). Of note, CD93
demonstrated a sixfold increased expression in CP-CML
LSCs compared with normal HSCs (p= 2.5 × 10−6). Gene
expression of CD26 and IL1-RAP were not significantly
different between the Lin−CD34+CD38−CD45RA−CD90+
LSC and HSC populations, perhaps due to the immature
phenotype of the cell type being analyzed.
CD93 is upregulated in CP-CML cells
Upregulation of CD93 gene expression was confirmed by
quantitative RT-PCR in both CD34+-selected peripheral
blood (PB) and BM (n= 30), compared with normal BM
samples (n= 5) (p < 0.0001; Fig. 2b). There was a sig-
nificant decrease in CD93 expression with maturation from
CD34+ to mononuclear cells (MNC) (p < 0.0001) in CML,
indicating that high expression of CD93 may be a specific
marker of primitive LSC in CML.
Next, we assessed CD93 protein expression on the LSC
population isolated from CP-CML PB samples (n= 22), and
CP-CML BM (n= 9) compared with normal samples (n= 7)
using FACS analysis and confirmed the significant upregu-
lation of CD93 protein on CML LSCs compared with normal
HSCs (p < 0.0001), where CD93 expression was absent/very
low (Fig. 2c). Thus, we hypothesized that the identification of
CD93 may define a functional LSC population.
CD93+, but not CD93−, CP-CML cells have stem cell
characteristics in vitro and in vivo
To assess the LSC potential of CD93+ and CD93− stem/
progenitor cells in vitro, CFC replating and LTC-IC assays
were performed on primary CP-CML samples sorted into
Lin−CD34+CD38-CD90+CD93+ (LSC-CD93+) and Lin−
CD34+CD38−CD90+CD93− (LSC-CD93−) populations
(Fig. S2). There was little difference in the ability of LSC-
CD93+ and LSC-CD93− to form CFCs in primary assays
(Fig. 3a). This perhaps reflects the ability of committed
progenitors to form colonies. Therefore, to assess self-
renewal, 50 primary colonies were picked, dispersed, and
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transferred to secondary replating assays and counted after
12 days in culture. The counts demonstrated a trend toward
an increase in percentage of positive wells in the LSC-
CD93+ population compared with LSC-CD93− (p= 0.09;
Fig. 3b), suggesting remaining LSC-CD93+ cells from
primary CFC plating have enhanced colony formation in
secondary CFC assays, likely through a more primitive
phenotype, compared with their LSC-CD93− counterparts.
To interrogate this further, the LTC-IC assay was uti-
lized. Results demonstrated a statistically significant
increase in colonies within the Lin−CD34+CD93+ popula-
tion with no, or few, colonies within the Lin−CD34+CD93−
population (p < 0.0001; Fig. 3c). This validated our pre-
vious finding that CD93+-selected cells have a more pri-
mitive phenotype, with increased self-renewal capacity
in vitro compared with CD93−-selected CML cells. To
determine whether this was due to differences in BCR-ABL
status, the two cell populations, Lin−CD34+CD93+ and
Lin−CD34+CD93- were interrogated by FISH for BCR-ABL
status. Analyzed cells from both fractions were shown to be
100% BCR-ABL positive (data not shown).
To validate whether Lin−CD34+CD93+ truly repre-
sented a more primitive CP-CML LSC fraction than Lin−
CD34+CD93−, xenotransplantation experiments using NSG
recipient mice were conducted. Prior to sorting, CP-CML
samples (n= 5) were determined to be >98% BCR-ABL
positive by FISH (Fig. S3). In experiments similar to those
described by Herrmann et al. for CD26 [10], Lin−CD34+
CD93+ or Lin−CD34+CD93− cells were transplanted via
tail vein injection into sub-lethally irradiated (2 Gy) 8–12-
week-old NSG mice (Fig. 3d). At 8 weeks post transplant,
PB was removed from the mice and analyzed for engraft-
ment using CD45 and CD33 expression by flow cytometry
(n= 3). There was no significant difference in CD45+
CD33+ expression between the Lin−CD34+CD93+ and
Lin−CD34+CD93− populations at this early time point
(Fig. S4). After 16 weeks, there was a statistically sig-
nificant increase in engraftment of human CD45+CD33+
cells within the BM of mice transplanted with Lin−CD34+
CD93+ cells from four independent CP-CML samples
(CML351 p= 0.015; CML393 p < 0.05; CML391 p <
0.0001; CML385 p= 0.0119) (Fig. 3e). Engraftment levels
were consistent with other CP-CML murine NSG models
[10, 27, 28]. Human CD45+CD33+ cells were isolated post
engraftment from NSG murine BM and analyzed by FISH
for the BCR-ABL gene rearrangement. These samples were
BCR-ABL positive (Fig. 3f) demonstrating that the CD93+-
selected population has an increased self-renewal capacity
and has stem cell-like characteristics.
Within a further CP-CML sample, there was no differ-
ence in engraftment (Fig. S5). However, engrafted cells
from the CD93− subpopulation were found to be of both
lymphoid and myeloid lineages and BCR-ABL negative,
with pre-engraftment FISH demonstrating a small, but
biologically significant percentage of BCR-ABL negative
cells (CML395; Fig. S3).
Taken together, these in vitro and in vivo results suggest
that the CD93+ population represents a more primitive self-
renewing population of CP-CML LSCs than CD93− cells
and is a more immature precursor population within the
leukemia stem and progenitor cell hierarchy.
As CD93+-selected populations have functional proper-
ties of CML LSC, with evidence of increased engraftment
potential, we hypothesized that those cells with less CD93
expression would have a more mature and less lineage-
restricted gene expression profile compared with LSC-
CD93+ cells. It was expected that as CD93 positivity
represents a spectrum of expression rather than a binary
system, that gene expression would also display this. Any
statistical results, therefore, would be extremely significant
(Fig. 4a). Using Fluidigm targeted gene analysis of 48 cell
survival and self-renewal genes, CD93 was demonstrated to
be upregulated within the FACS-sorted LSC-CD93+
population compared with LSC-CD93− population (p=
0.0068) (Fig. 4b). A number of genes involved in lineage
restriction and cell cycle were statistically different in the
LSC-CD93− population, including GATA1 (p= 0.0007),
CBX8 (p= 0.0002), and CYCLIND2 (p < 0.01) (Fig. 4 c).
Moreover, the LSC-CD93+ population overexpressed a
number of genes associated with HSC regulation, including
C-KIT (p= 0.0014) and CDK6 (p= 0.05) (Fig. 4d).
We next utilized single-cell gene expression using Flui-
digm C1 technology to corroborate these findings. CP-CML
cells were sorted into (1) lin−CD34+, (2) LSC-CD93−, and
(3) LSC-CD93+ populations. Single cells were sorted into
each population across two individual CP-CML samples
(n= 150 LSC-CD93+, n= 150 LSC-CD93− single cells.
The frequency of expression [29] for each gene was deter-
mined. A total of 20 genes had a higher frequency within the
CD93+, and 53 genes had a higher frequency within the
CD93−-selected single-cell populations (Fig. S6). Next, a
threshold of 10 events for population per chip was set for
analyzing individual genes. Using a Kolmogorov–Smirnov
Fig. 2 CD93 expression can isolate a functional stem cell popula-
tion in CML. a Analysis of the microarray, GSE47927, demonstrated
a significant fold change between CP-CML LSCs and normal HSCs in
genes for cell surface proteins. The table represents the most statisti-
cally significant cell surface marker genes identified. b RNA from 30
BM and PB CP-CML samples was utilized to validate the gene
expression of CD93. MNC and CD34+-selected (n= 30) samples were
compared with normal BM (n= 5). c CD93 protein expression was
assessed by flow cytometry in lin−CD34+CD38−CD90+ populations
between CML (peripheral blood [n= 22] and BM [n= 9]) and normal
BM (n= 7). A statistically significant increase in percentage of CD93+
cells in CML was determined using an unpaired Student’s t test (p <
0.0001). MNC; mononuclear cells, PB; peripheral blood, BM; bone
marrow.
R. Kinstrie et al.
Fig. 3 CD93+, but not CD93−, CP-CML cells have stem cell
characteristics in vitro and in vivo. a CP-CML samples (n= 4) were
sorted according to Fig. S2 and plated in duplicate into Methocult for
10–12 days prior to colony counts. The graph indicates the mean
number of colonies for each CP-CML sample, with mean and standard
deviation for each population shown. b 50 primary colonies per
sample were replated in Methocult in 96 well plates and incubated at
37°, 5% CO2 for 12 days before positive wells were counted. The
graph indicates the percentage of positive wells per population (n= 4
CP-CML samples), with mean and standard deviation shown. c The
graph indicates the number of colonies from each experimental arm
(n= 3 CP-CML samples), with mean and standard deviation shown.
d Representation of in vivo experimental model. CP-CML Lin−
CD34+CD93+ or Lin−CD34+CD93− cells were isolated by FACS
sorting (1 × 106 cells/mouse), washed and transplanted via tail vein
injection into sub-lethally irradiated (2 Gy) 8–12-week-old NSG mice.
PB was sampled at 8 weeks to assess for CD45+33+ expression. All
mice were euthanized after 16 weeks and marrow contents of femurs
were obtained. Cells were labeled with anti-human CD45, CD33, and
CD19 antibodies prior to analysis by flow cytometry. This allowed for
analysis of lineages within the engrafted samples. e Human myeloid
cell engraftment was characterized by the percentage of CD45+CD33+
cells. f Human CD45+ cells were isolated by FACS sorting and ana-
lyzed by FISH for the BCR-ABL gene rearrangement. Percentage of
BCR-ABL positive cells, as determined from analysis of a minimum of
100 cells, was assessed for each murine experiment.
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Fig. 4 Gene expression profiling of bulk CD93-selected CP-CML
LSCs confirms their quiescent character. a Schematic diagram of
CD93 expression within a stem cell population. b CD93 gene
expression as determined in the lin−CD34+CD38−CD90+CD93+ and
lin−CD34+CD38−CD90+CD93− population (p= 0.0068). Results are
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were overexpressed in the lin−CD34+CD38−CD90+CD93− popula-
tion, namely GATA1 and CBX8. d Key genes involved in stem cell
maintenance were upregulated in the lin−CD34+CD38−CD90+CD93+
population. e Normalized differential gene expression of the single
cells using the ΔΔCt method. The control sample is the mean of the
CD93− on each chip. GATA1 was significantly downregulated in the
CD93+ population (n= 2 CP-CML samples, q= 0.03). f Principal
component analysis (PCA) of the four different populations defined by
CD93 surface presence and BCR-ABL1 expression. Each individual
dot represents a single cell. It can be observed that the CD93+ BCR-
ABL1+ cells (in red) are more heterogeneous than the other popula-
tions and that they form a slightly different cluster.
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test and correcting for false discovery rate with p < 0.05 [23],
GATA1 expression was significantly lower in the CD93+
single cells (Fig. 4e; Table 1), but no other significant
changes were identified.
Furthermore, hierarchical gene clustering could not
clearly discriminate between CD93+ and CD93− popula-
tions at a single-cell level, and therefore highlighted the
heterogeneity within the two populations by single-cell
analysis (Fig. S7). Furthermore, PCA of four different
populations defined by CD93 and BCR-ABL1 expression
demonstrated that the CD93+BCR-ABL1+ cells were more
heterogeneous than the other populations (Fig. 4f). There
was an increasing trend towards CD93+ cells being BCR-
ABL1+ by multiplex PCR. The changes within frequency
and gene expression are subtle within a single-cell approach
and small changes or trends may be biologically important.
Overall, these data suggest that CD93+ selection confers
cell immaturity and self-renewal capability, with the
majority of this population retaining BCR-ABL expression.
TKIs downregulate CD93, but do not eliminate
CD93+ LSC even after prolonged in vivo therapy
We next sought to determine if CD93 expression would
alter following TKI exposure. Lin−CD34+ CP-CML sam-
ples (n= 3) were cultured in the presence of imatinib or
dasatinib. Baseline CD93 expression was analyzed by flow
cytometry. After 24 h, cells were washed of TKI and cul-
tured for a further 24 h before flow cytometric expression of
CD93 was analyzed. Results suggested that TKIs reduce but
do not eliminate CD93 expression (Fig. 5a, b). Next, CD93
expression was assessed in a Nilotinib-treated PDX model
from two different patient samples. CD93 expression was
assessed in the hCD45+CD34+CD38− population. Again,
TKI treatment did not eliminate CD93 expression (Fig. 5c).
It was noted, however, that there was an interpatient
variability in expression when using the PDX model. This
led us to question if CD93 expression represents a self-
renewing population in CP-CML cells, and if it is not
eliminated by TKI, could it be detected in patients who have
been treated by TKI and subsequently relapse following
TKI withdrawal.
BM samples of patients in MR4 (BCR-ABL1:ABL1
ratio of <0.01%), taken at entry into the DESTINY clinical
trial (NCT01804985) [19], who either remained in MMR or
better for at least 3 years (n= 4) or developed molecular
recurrence (n= 4) after TKI discontinuation were thawed
and cultured as previously described. Samples were sorted
into LSC-CD93− and LSC-CD93+ populations. A sig-
nificant increase in CD93 expressing LSCs were identified
in patients with molecular recurrence compared with those
in sustained MMR or better (Fig. 5d; p= 0.006); the
majority of these cells were BCR-ABL1+ by FISH
(Fig. S8A, B), suggesting a persisting LSC population.
Discussion
We have presented functional and genomic data demon-
strating that CD93 expression may be utilized to identify
CML cells with stem cell-like capability. Further to this, we
have identified that CD93 expression persists despite
Table 1 Single-cell gene expression profiling identifies that CD93
+-selected single cells have a stem cell signature.
Gene p value q value Gene p value q value
ADAM17 0.273 0.650 INK4D 0.310 0.668
BCR 0.266 0.650 KLF4 0.018 0.336
BMI1 0.456 0.777 LMO2 0.951 0.992
CBX2 0.759 0.963 MAFB 0.723 0.955
CCND2 0.992 0.992 MCM2 0.264 0.650
CCND3 0.188 0.650 MCM3 0.459 0.777
CD93 0.900 0.992 MCM4 0.281 0.650
CDK6 0.267 0.650 MCM7 0.314 0.668
CDKN2B 0.268 0.650 MCM9 0.640 0.903
CEBPA 0.194 0.650 MDM2 0.657 0.903
CITED2 0.604 0.886 MEIS1 0.603 0.886
C-KIT 0.503 0.829 MPL 0.033 0.366
CMYC 0.011 0.336 NFE2 0.122 0.650
CSF1R 0.100 0.650 NOTCH1 0.447 0.777
CSF2R 0.040 0.366 NOTCH2 0.068 0.496
CXCR4 0.991 0.992 NUMB 0.020 0.336
EGR1 0.963 0.992 ORC2 0.914 0.992
ENG 0.880 0.992 p210 0.278 0.650
FBXW7 0.161 0.650 PBX1 0.561 0.886
FLI1 0.905 0.992 PREP1 0.590 0.886
FLT1 0.044 0.366 PU1 0.262 0.650
FLT3 0.942 0.992 RUNX1 0.286 0.650
GATA1 0.0005 0.031 SCA1 0.420 0.770
GATA2 0.394 0.764 SCL 0.646 0.903
GFI1 0.029 0.366 SPI1 0.140 0.650
HLF 0.970 0.992 STIL 0.983 0.992
HOXA5 0.709 0.955 TIE1 0.150 0.650
HOXA6 0.212 0.650 TLE3 0.352 0.726
HOXA9 0.749 0.963 TP53 0.394 0.764
HOXB4 0.817 0.992 TWY1 0.882 0.992
IKZF1 0.418 0.770 VEGFA 0.209 0.650
IL3RA 0.593 0.886 VWF 0.808 0.992
INK4C 0.207 0.650 XRCC3 0.247 0.650
Using a Kolmogorov–Smirnov test and correcting for false discovery
rate with p < 0.05, GATA1 expression was statistically significant
(based on the q value) between CD93− and CD93+ populations
The bold highlighted text is the only statistically significant result in
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prolonged TKI exposure in those patients with molecular
recurrence upon TKI discontinuation.
We initially identified the Lin−CD34+CD38−CD45RA−
CD90+ CP-CML stem/progenitor subpopulation as having
greater proliferative and colony-forming capacity than nor-
mal HSCs. CD93 had increased expression in CML LSCs
compared with normal HSCs, and in vitro and in vivo
analysis confirmed the stem cell-like capacity of the CP-
CML CD93+ population. Initial in vitro analysis of clonal
progenitor assays demonstrated minimal differences in
colony-forming capacity between lin−CD34+CD38−CD90+
CD93+ and lin−CD34+CD38−CD90+CD93− populations.
This is unsurprising as the ability to form a multilineage
colony focuses on the ability to differentiate, with only
limited involvement of self-renewal [30]. LTC-IC assays
were utilized to determine quantitative assessment of LSC
function [30, 31], as the most stringent in vitro surrogate
measure of the functional activity of HSCs/LSCs [31]. Our
results demonstrated a statistically significant increase in
colonies within the lin−CD34+CD93+ experimental arm
(p= 0.0001), suggesting that CD93+-selected cells have
increased in vitro stem cell-like capacity. Because in vitro
measurements of self-renewal do not reflect the complex
multidirectional interactions seen within the BM, we utilized
an in vivo NSG engraftment model to determine if the
CD93+-selected population could be truly representative of
an enhanced self-renewing population. Within four inde-
pendent CP-CML samples, there was a statistically sig-
nificant increase in engraftment of CD93+ compared with
CD93−-selected populations. All levels of engraftment were
within the previously published range for a CP-CML in vivo
model [10, 27, 28]. This verified our previous findings that
the CD93+-selected population has functional properties of
LSCs, with the evidence of increased engraftment potential.
This is an intriguing finding, as an LSC immunophenotype
was not used for the LTC-IC assay, nor the in vivo com-
ponent due to low cell numbers, suggesting that CD93 is
discriminating between a functional LSC (i.e., those with
self-renewing capability) and more mature cells within the
stem cell compartment. Further to this, CD93 expression
was not eliminated by TKI and persisted in patients with
prolonged TKI exposure (>3 years) who developed mole-
cular recurrence upon TKI withdrawal.
Many groups have attempted to identify novel cell sur-
face markers of the CML LSC. Included in these are CD25,
IL1-RAP, and CD26, identified within a CD34+CD38−/low
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Fig. 5 TKIs downregulate CD93, but do not eliminate CD93+ LSC
even after prolonged in vivo therapy. CP-CML cells (n= 3) were
thawed and sorted into an LSC population before culturing in SFM
plus physiological growth factors with and without Imatinib (a) or
Dasatinib (b). Following culture for 24 h, half of the samples were
analyzed by flow cytometry to assess CD93 expression. The rest were
thoroughly washed to completely remove TKI and re-cultured in SFM
supplemented with physiological growth factors for a further 24 h prior
to flow cytometry analysis. c A nilotinib-treated PDX model was used
to determine CD93+ cells in the hCD45+CD34+CD38− population
by flow cytometry. This demonstrates persistence of CD93 expression
despite TKI treatment in two patient samples. d CD93 expression as
determined by flow cytometry in eight patients with prolonged TKI
treatment. Within patients who relapsed post TKI discontinuation, a
small lin−CD34+CD38−CD90+CD93+ population could be identified,
compared with patients who did not demonstrate a molecular relapse.
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CML stem/progenitor cell population [9, 32, 33]. IL1-RAP
and CD26 are arguably the most well established, and have
been shown to separate BCR-ABL positive and negative cell
populations, as well as being investigated for their potential
for targeting therapeutically [10, 11, 34]. CD26 has shown
promise within clinical translation, with data indicating
CML LSCs specifically express CD26, with its function
disrupting interactions within the stem cell niche [10], and
its expression being correlated with both leukocyte count
and treatment response [8]. Recent studies indicate the most
TKI-insensitive cells can be captured within a Lin−CD34+
CD38−/lowCD45RA−cKIT−CD26+ population, suggesting
this fraction of cells as a potential therapeutic target [13].
However, a recent publication has demonstrated that
although vildagliptin, a dipeptidyl-peptidase IV (CD26)
inhibitor, reduced LSC mobilization in an in vitro co-culture
model, there was no significant effects in a NSG (PDX)
model when combined with TKI therapy, perhaps high-
lighting the complexity of CD26 within a multidirectional
niche system [35]. The initial identification of CD26 and
IL1-RAP was based on a more mature cell population,
namely CD34+CD38−/low, and not the very primitive Lin−
CD34+CD38−CD45RA−CD90+ evaluated here. Therefore,
differences in CD93 expression would be missed in these
previous studies as its preferential expression on LSCs lies
within a significantly more primitive population. This was
highlighted in a recent study by Warfvinge et al., where
CD93 expression was shown within the MNC fraction of
both normal and CML samples [13]. Our data similarly
demonstrated that within a MNC population there is limited
expression of CD93 in both normal and CML. However,
our findings of increased CD93 expression and its impor-
tance is based on its presence on the LSC population,
immunophenotypically defined as Lin−CD34+CD38−
CD45RA−CD90+.
To conclude, we report the selective expression of CD93
on immature CML cells and the associated self-renewing
nature of this primitive cell subpopulation. As CD93 is
expressed on endothelial cells, platelets and other critical
cell types, it is unlikely that CD93 can be targeted ther-
apeutically [16, 17]. CD93 has been previously described as
an immature marker on a rare CD34− population of human
HSCs, which have self-renewal and repopulating capacities
[36], and on AML LSCs [18, 37], most specifically on
MLL-rearranged AML. Therefore, it is likely that there is a
role for CD93 within stem cell phenotypes, although its
precise function(s) remains to be elucidated. In preliminary
experiments, we are exploring whether CD93 had a role in
LSC adherence within the BM niche. CD93 has been
identified as a key mediator of integrin α5β1 interaction
with fibronectin [38]. Furthermore, it has been previously
reported that α5β1 is implicated in CP-CML LSC binding to
fibronectin through CD44 [39, 40]. This will be fully
evaluated in ongoing and future studies. Finally, identifying
primitive CML cells with self-renewing capability, which
persist throughout treatment, and may be responsible for
molecular recurrence, is becoming increasingly important in
an era where TKI withdrawal is becoming standard-of-care
for some patients. The possible discovery of a predictive
biomarker, namely CD93, to distinguish those patients at
high risk of molecular recurrence, if validated, could
become an important test for patients considering TFR, and
could also have the potential to identify patients suitable for
future TFR trials.
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